## Mikila R Jacobson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3794623/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. New England Journal of Medicine, 1999, 341, 468-475.	27.0	1,256
2	Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity. Journal of Immunology, 2004, 172, 3252-3259.	0.8	496
3	Allergen injection immunotherapy for seasonal allergic rhinitis. The Cochrane Library, 2007, , CD001936.	2.8	385
4	Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-Î <sup>3</sup> . Journal of Allergy and Clinical Immunology, 1996, 97, 1356-1365.	2.9	383
5	Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. Journal of Allergy and Clinical Immunology, 2011, 127, 509-516.e5.	2.9	299
6	Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa. Journal of Allergy and Clinical Immunology, 2008, 121, 1467-1472.e1.	2.9	285
7	Grass Pollen Immunotherapy Induces an Allergen-Specific IgA2 Antibody Response Associated with Mucosal TGF-β Expression. Journal of Immunology, 2007, 178, 4658-4666.	0.8	216
8	Expression of É› germ-line gene transcripts and mRNA for the É› heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. European Journal of Immunology, 1997, 27, 2899-2906.	2.9	163
9	Objective monitoring of nasal airway inflammation in rhinitis. Journal of Allergy and Clinical Immunology, 2005, 115, S414-S441.	2.9	123
10	Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. Journal of Allergy and Clinical Immunology, 2001, 107, 971-976.	2.9	115
11	Basophil recruitment and IL-4 production during human allergen-induced late asthma. Journal of Allergy and Clinical Immunology, 2001, 108, 205-211.	2.9	102
12	IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy. Journal of Allergy and Clinical Immunology, 2005, 116, 73-79.	2.9	99
13	Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individuals. Journal of Allergy and Clinical Immunology, 1994, 94, 764-772.	2.9	91
14	Expression of IL-4, CΪμ RNA, and IΪμ RNA in the nasal mucosa of patients with seasonal rhinitis: Effect of topical corticosteroidsã`†ẫ`†ẫ`ẫ`ẫ` Journal of Allergy and Clinical Immunology, 1998, 101, 330-336.	2.9	79
15	IL-13 mRNA and Immunoreactivity in Allergen-induced Rhinitis: Comparison with IL-4 Expression and Modulation by Topical Glucocorticoid Therapy. American Journal of Respiratory Cell and Molecular Biology, 1997, 17, 17-24.	2.9	77
16	Is occupational asthma to diisocyanates a non–IgE-mediated disease?. Journal of Allergy and Clinical Immunology, 2006, 117, 663-669.	2.9	73
17	CCR4 in human allergen-induced late responses in the skin and lung. European Journal of Immunology, 2002, 32, 1933.	2.9	60
18	Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. Journal of Allergy and Clinical Immunology, 2000, 106, 293-301.	2.9	49

Mikila R Jacobson

#	Article	IF	CITATIONS
19	Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment. Journal of Allergy and Clinical Immunology, 1997, 100, 569-574.	2.9	43
20	Severe Persistent Allergic Rhinitis. Inflammation but No Histologic Features of Structural Upper Airway Remodeling. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1431-1439.	5.6	36
21	CXCR1+CD4+T Cells in Human Allergic Disease. Journal of Immunology, 2004, 172, 268-273.	0.8	24
22	Repetitive nasal allergen challenge in allergic rhinitis: Priming and Th2â€ŧype inflammation but no evidence of remodelling. Clinical and Experimental Allergy, 2021, 51, 329-338.	2.9	22
23	Grass pollen immunotherapy (IT) increases IL-10- and TGF-β-mRNA expression in the nasal mucosa during the pollen season. Journal of Allergy and Clinical Immunology, 2002, 109, S171-S171.	2.9	3
24	Cochrane review: Allergen injection immunotherapy for seasonal allergic rhinitis. Evidence-Based Child Health: A Cochrane Review Journal, 2010, 5, 1279-1379.	2.0	3
25	Allergen injection immunotherapy for perennial allergic rhinitis. The Cochrane Library, 2008, , .	2.8	2
26	Regulation of CCR4 expression after segmental bronchial allergen challenge in atopic asthmatics. Journal of Allergy and Clinical Immunology, 2002, 109, S41-S41.	2.9	1
27	Inhibition of nasal mucosal eosinophils after immunotherapy is associated with a decrease in interleukin-13 mRNA and vascular cell adhesion molecule-1 expression. Allergology International, 2004, 53, 255-264.	3.3	1
28	Despite Inflammation, No Structural Upper Airway Remodelling In Severe Allergic Rhinitis. Journal of Allergy and Clinical Immunology, 2014, 133, AB145.	2.9	1